Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: Potential for rapid monitoring of treatment responses

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 11, 2012, Pages 1993-1998

  Ulmert, David ^a,b   Vickers, Andrew J ^c   Scher, Howard I ^c,d   Becker, Charlotte ^b   Iversen, Peter ^e   Frankel, David ^f   Jensen, Jens Kristian ^f   Olesen, Tine Kold ^f   Lilja, Hans ^b,c  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f Ferring Pharmaceuticals AS   (Denmark)

Author keywords

Androgen deprivation therapy; Human kallikrein related peptidase 2; Prostate cancer; Prostate specific antigen; Tumor markers

Indexed keywords

ANDROGEN RECEPTOR; DEGARELIX; KALLIKREIN RELATED PEPTIDASE 2; PHARMACOLOGICAL BIOMARKER; PROSTATE SPECIFIC ANTIGEN; SERINE PROTEINASE; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BLOOD SAMPLING; CANCER HORMONE THERAPY; CASTRATION; CLINICAL ARTICLE; DRUG EFFECT; DRUG MECHANISM; DRUG MONITORING; HUMAN; IMMUNOFLUORESCENCE TEST; MALE; MULTICENTER STUDY; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; PROTEIN BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL; TREATMENT RESPONSE;

AGED; GONADOTROPIN-RELEASING HORMONE; HUMANS; KALLIKREINS; KINETICS; MALE; MIDDLE AGED; OLIGOPEPTIDES; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

IPSA;

EID: 84872904175     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2011-0967     Document Type: Article

References (31)

1. Chapdelaine P, Paradis G, Tremblay RR, Dube JY. High level of expression in the prostate of a human glandular kallikrein mRNA related to prostate-specific antigen. FEBS Lett 1988;236:205-8.
2. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen, 1979. J Urol 2002;167:960 - 4; discussion 4-5.
3. Ahlgren G, Rannevik G, Lilja H. Impaired secretory function of the prostate in men with oligo-asthenozoospermia. J Androl 1995;16:491-8.
4. Becker C, Noldus J, Diamandis E, Lilja H. The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease. Crit Rev Clin Lab Sci 2001;38:357-995.
5. Vickers A, Cronin A, Roobol M, Savage C, Peltola M, Pettersson K, et al. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol 2010;28:2493-8.
6. Steuber T, Vickers A, Haese A, Kattan MW, Eastham JA, Scardino PT, et al. Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. Int J Cancer 2007;120:1499-504.
7. Nurmikko P, Pettersson K, Piironen T, Hugosson J, Lilja H. Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146. Clin Chem 2001;47:1415-23.
8. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008;8:268-78.
9. Vaisanen V, Eriksson S, Ivaska KK, Lilja H, Nurmi M, Pettersson K. Development of sensitive immunoassays for free and total human glandular kallikrein 2. Clin Chem 2004;50:1607-17.
10. Bruun L, Ekberg H, Bjork T, Lilja H, Hoglund P, Christensson A. Rapid elimination by glomerular filtration of free prostate specific antigen and human kallikrein 2 after renal transplantation. J Urol 2004;171:1432-5.
11. Kilic S, Yalcinkaya S, Guntekin E, Kukul E, Deger N, Sevuk M. Determination of the site of metabolism of total, free, and complexed prostate-specific antigen. Urology 1998;52:470-3.
12. Bjork T, Ljungberg B, Piironen T, Abrahamsson PA, Pettersson K, Cockett AT, et al. Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to alpha 1-antichymotrypsin from serum. Urology 1998;51:57-62.
13. Pizzo SV, Mast AE, Feldman SR, Salvesen G. In vivo catabolism of alpha 1-antichymotrypsin is mediated by the Serpin receptor which binds alpha 1-proteinase inhibitor, antithrombin III and heparin cofactor II. Biochim Biophys Acta 1988;967:158-62.
14. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366:981-90.
15. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
16. Holmstrom B, Johansson M, Bergh A, Stenman UH, Hallmans G, Stattin P. Prostate specific antigen for early detection of prostate cancer: longitudinal study. Br Med J 2009;339: b3537.
17. Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ Jr, Lilja H, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006;24:3973-8.
18. Lilja H, Haese A, Bjork T, Friedrich MG, Piironen T, Pettersson K, et al. Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy. J Urol 1999;162:2029 - 34; discussion 34-5.
19. Bjork T, Schalken J, Wittjes W, Ljungberg B, Lilja H. Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues. Prostate 2001;47:14-20.
20. Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallelgroup phase III study in patients with prostate cancer. BJU Int 2008;102:1531-8.
21. Van Poppel H, Tombal B, de la Rosette JJ, Persson BE, Jensen JK, Kold Olesen T. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker - results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol 2008;54:805-13.
22. Jiang G, Stalewski J, Galyean R, Dykert J, Schteingart C, Broqua P, et al. GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6. J Med Chem 2001;44:453-67.
23. Broqua P, Riviere PJ, Conn PM, Rivier JE, Aubert ML, Junien JL. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. J Pharmacol Exp Ther 2002;301:95-102.
24. Piironen T, Lovgren J, Karp M, Eerola R, Lundwall A, Dowell B, et al. Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum. Clin Chem 1996;42:1034-41.
25. Lilja H, Ulmert D, Bjork T, Becker C, Serio AM, Nilsson JA, et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol 2007;25:431-6.
26. Becker C, Piironen T, Kiviniemi J, Lilja H, Pettersson K. Sensitive and specific immunodetection of human glandular kallikrein 2 in serum. Clin Chem 2000;46:198-206.
27. Nurmikko P, Vaisanen V, Piironen T, Lindgren S, Lilja H, Pettersson K. Production and characterization of novel antiprostate-specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys145-Lys146 inactive PSA. Clin Chem 2000;46:1610-8.
28. Christensson A, Bruun L, Björk T, Cronin AM, Vickers AJ, Savage CJ, et al. Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serialcollection of blood from men under evaluation for prostate cancer. BJU Int 2011;107:1769-74.
29. Steuber T, Niemela P, Haese A, Pettersson K, Erbersdobler A, Felix Chun KH, et al. Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue. Prostate 2005;63:13-8.
30. Haese A, Graefen M, Steuber T, Becker C, Noldus J, Erbersdobler A, et al. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specificantigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies. J Urol 2003;170:2269-73.
31. Haese A, Vaisanen V, Lilja H, Kattan MW, Rittenhouse HG, Pettersson K, et al. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade. J Urol 2005;173:752-6.